FCA
LTRN icon

FinTrust Capital Advisors’s Lantern Pharma LTRN Stock Holding History

FinTrust Capital Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-90
Closed -$2 – 1118
2020
Q3 		$2 Buy
+90
New +$1.3K ﹤0.01% 1064

Other funds holding LTRN

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FinTrust Capital Advisors's LTRN Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of Lantern Pharma (LTRN) in Q4 2020, closing a stake of 90 shares — an estimated $2 sold.

FinTrust Capital Advisors first reported a position in LTRN in Q3 2020 and held it in 1 quarter. The position peaked at $2 in Q3 2020. 10 funds tracked by Wall St. Rank hold LTRN as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining Lantern Pharma position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 90 Lantern Pharma shares in Q4 2020, an estimated $2.
  • FinTrust Capital Advisors first reported a position in Lantern Pharma in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's Lantern Pharma position peaked at $2 in Q3 2020.
  • 10 funds tracked by Wall St. Rank held Lantern Pharma as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.